HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Werewolf Therapeutics (NASDAQ:HOWL) and maintained a $15 price target.

May 06, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Werewolf Therapeutics with a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside based on the firm's analysis. This can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100